

What is Claimed is:

1. In a conjugate comprising a taxoid and an omega-3 fatty acid, the improvement wherein the taxoid is a second-generation taxoid.
2. A conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1214.
3. A conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1213.
4. A conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1216.
5. A conjugate according to claim 1, wherein the second-generation taxoid is SB-T-1103.
6. A conjugate according to claim 1, wherein the second-generation taxoid is ortataxel.
7. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-11033.
8. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-1104.
9. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-11043.
10. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-1107.
11. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-11073.
12. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-121303.
13. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-121403.

14. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-121603.
15. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-121703.
16. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-12821.
17. A conjugated according to claim 1, wherein the second-generation taxoid is SB-T-128221-3.
18. A conjugate according to claim 1, wherein the omega-3 fatty acid is docosahexanoic acid.
19. A conjugate according to claim 1, wherein the omega-3 fatty acid is eicosapentaenoic acid.
20. A conjugate according to claim 1, wherein the omega-3 fatty acid is α -linolenic acid.
21. In a pharmaceutical composition comprising a conjugate comprising a taxoid and an omega 3-fatty acid, the improvement wherein the taxoid is a second-generation taxoid.
22. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is ortataxel.
23. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-121303.
24. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1103.

25. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1214.
26. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1216.
27. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-11033.
28. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1104.
29. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-11043.
30. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1107.
31. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-11073.
32. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-1213.
33. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-121403.
34. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-121603.

35. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-121703.
36. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-12821.
37. A pharmaceutical composition according to claim 21, wherein the second-generation taxoid is SB-T-128221-3.
38. A pharmaceutical composition according to claim 21, wherein the omega-3 fatty acid is docosahexanoic acid.
39. A pharmaceutical composition according to claim 21, wherein the omega-3 fatty acid is eicosapentaenoic acid.
40. A pharmaceutical composition according to claim 21, wherein the omega-3 fatty acid is α -linolenic acid.
41. In a method for treating cancer in a human in need thereof, the method comprising administering an effective amount of a conjugate comprising a taxoid and an omega 3-fatty acid, the improvement wherein the taxoid is a second-generation taxoid.
42. A method according to claim 41, wherein the second-generation taxoid is ortataxel.
43. A method according to claim 41, wherein the second-generation taxoid is SB-T-121303.
44. A method according to claim 41, wherein the second-generation taxoid is SB-T-1103.
45. A method according to claim 41, wherein the second-generation taxoid is SB-T-1214.
46. A method according to claim 41, wherein the second-generation taxoid is SB-T-1216.

47. A method according to claim 41, wherein the second-generation taxoid is SB-T-11033.
48. A method according to claim 41, wherein the second-generation taxoid is SB-T-1104.
49. A method according to claim 41, wherein the second-generation taxoid is SB-T-11043.
50. A method according to claim 41, wherein the second-generation taxoid is SB-T-1107.
51. A method according to claim 41, wherein the second-generation taxoid is SB-T-11073.
52. A method according to claim 41, wherein the second-generation taxoid is SB-T-1213.
53. A method according to claim 41, wherein the second-generation taxoid is SB-T-121403.
54. A method according to claim 41, wherein the second-generation taxoid is SB-T-121603.
55. A method according to claim 41, wherein the second-generation taxoid is SB-T-121703.
56. A method according to claim 41, wherein the second-generation taxoid is SB-T-12821.
57. A method according to claim 41, wherein the second-generation taxoid is SB-T-128221-3.
58. A method according to claim 41, wherein the omega-3 fatty acid is docosahexanoic acid.
59. A method according to claim 41, wherein the omega-3 fatty acid is eicosapentaenoic acid.
60. A method according to claim 41, wherein the omega-3 fatty acid is α -linolenic acid.

61. A method according to claim 41, wherein the cancer is breast cancer.
62. A method according to claim 41, wherein the cancer is ovarian cancer.
63. A method according to claim 41, wherein the cancer is lung cancer.
64. A method according to claim 41, wherein the cancer is head cancer.
65. A method according to claim 41, wherein the cancer is neck cancer.
66. A method according to claim 41, wherein the cancer is colon cancer.
67. A method according to claim 41, wherein the cancer is pancreatic cancer.
68. A method according to claim 41, wherein the cancer is melanoma cancer.
69. A method according to claim 41, wherein the cancer is brain cancer.
70. A method according to claim 41, wherein the cancer is renal cancer.
71. A method according to claim 41, wherein the cancer is prostate cancer.